Detalhe da pesquisa
1.
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Future Oncol
; 16(16): 1083-1189, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32356465
2.
Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients.
J Psychosoc Oncol
; 37(4): 427-440, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30798774
3.
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.
Technol Cancer Res Treat
; 22: 15330338231154088, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016933
4.
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial.
Eur Urol Focus
; 9(2): 317-324, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36154809
5.
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Eur Urol Oncol
; 2023 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37821242
6.
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Radiother Oncol
; 172: 1-9, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476942
7.
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Eur Urol Focus
; 7(2): 241-244, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33386290
8.
Oligometastatic prostate cancer: The game is afoot.
Cancer Treat Rev
; 73: 84-90, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30684842